Abstract
The advent of pathology-specific diagnostic methods such as amyloid positron emission tomography (PET) and tau PET has enabled early and pre-symptomatic diagnosis of Alzheimer's disease. Imaging biomarkers in nuclear medicine play a key role in elucidating the pathogenesis of Alzheimer's disease and accelerating the development of disease-modifying drugs. In this study, we describe the current status and future prospects of nuclear medicine diagnostics aimed at early detection of Alzheimer's disease to delay and prevent disease progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
